1 – 10 of 148
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
(
- Contribution to journal › Article
-
Mark
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. Reply
(
- Contribution to journal › Letter
-
Mark
Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia
(
- Contribution to journal › Article
-
Mark
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
(
- Contribution to journal › Article
- 2023
-
Mark
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
(
- Contribution to journal › Article
-
Mark
Timing of Primary Surgery for Cleft Palate
(
- Contribution to journal › Article
-
Mark
SARS-CoV-2 - No Increased Islet Autoimmunity or Type 1 Diabetes in Teens
(
- Contribution to journal › Letter
-
Mark
Cystatin C–Based Equation to Estimate GFR without the Inclusion of Race and Sex
(
- Contribution to journal › Article
-
Mark
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
(
- Contribution to journal › Letter
-
Mark
Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
(
- Contribution to journal › Article